文献速递慢性肾脏病血液净化与透析水电解质与酸碱

血液透析低骨量患者使用地舒单抗后的低钙血症与骨密度变化

Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

这项为期2年的观察性非对照研究纳入47例血液透析患者,发现地舒单抗相关急性低钙血症(DAAH)发生率为25.5%。基线骨碱性磷酸酶独立预测血清校正钙下降,抗酒石酸酸性磷酸酶-5b预测DAAH的AUC为0.750。24个月时腰椎和股骨颈骨密度分别显著增加5.9%和4.2%。

要点

  • 血透患者地舒单抗相关急性低钙血症发生率为25.5%
  • 基线骨碱性磷酸酶独立预测地舒单抗后校正钙下降
  • 地舒单抗治疗24个月显著增加腰椎和股骨颈骨密度

核心结论

  • 在高周转骨代谢的血透患者中,地舒单抗诱导的钙下降风险更高,但治疗24个月可显著提升腰椎和股骨颈骨密度。

研究设计与样本

  • 观察性非对照研究,纳入47例血液透析患者,随访24个月。

主要发现

  • 地舒单抗相关急性低钙血症(血清校正钙≤8 mg/dL)发生率为25.5%。
  • 基线骨碱性磷酸酶与校正钙百分比变化独立相关(β=-0.407,P=0.008)。
  • 抗酒石酸酸性磷酸酶-5b预测DAAH的AUC为0.750(95%CI 0.546-0.954;P=0.02),最佳截断值670 mU/mL,敏感性0.727,特异性0.733。
  • 24个月时腰椎骨密度显著增加5.9±1.7%(P=0.01),股骨颈增加4.2±1.5%(P=0.04)。

关键数值与推荐

  • DAAH定义为血清校正钙≤8 mg/dL。
  • 抗酒石酸酸性磷酸酶-5b预测DAAH的最佳截断值为670 mU/mL。

临床怎么用

  • 血透患者使用地舒单抗前应评估骨转换标志物,高骨碱性磷酸酶或TRAP-5b升高者需警惕低钙血症并加强监测。

局限性

  • 研究为非对照观察性设计,样本量较小(47例),结果需更大规模对照研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increases in bone mineral density (BMD) following a single dose of denosumab and increased incidence of denosumab-associated acute hypocalcemia (DAAH) have been reported in chronic kidney disease patients. Little is known about clinical risk factors related to DAAH and the long-term effect of denosumab on BMD in hemodialysis patients. METHODS: An observational noncontrolled study involving 47 hemodialysis patients was conducted to determine the independent risk factors related to percentage changes in serum calcium (Ca) levels associated with denosumab using multivariate regression analysis. Optimal predictive markers for DAAH were explored by receiver operating characteristic analysis. Percentage changes of BMD at the lumbar spine (LS) and femoral neck (FN) at 24 months were investigated. RESULTS: The incidence of DAAH [serum corrected Ca (cCa) ≤8 mg/dL] following denosumab was 25.5%. Multivariate regression analysis showed that baseline bone alkaline phosphatase was independently related to percentage changes in cCa levels (β = -0.407, P = 0.008). Tartrate-resistant acid phosphatase-5b was found to be the most accurate marker to predict DAAH, with an area under the curve of 0.750 (95% confidence interval 0.546-0.954; P = 0.02), and the optimal cut-off level was 670 mU/mL with sensitivity: 0.727 and specificity: 0.733. BMD significantly increased by 5.9 ± 1.7% (P = 0.01) at LS and 4.2 ± 1.5% (P = 0.04) at FN at 24 months. CONCLUSIONS: In hemodialysis patients, high bone turnover was an independent risk factor for the Ca declines induced by denosumab. Denosumab significantly increased BMD at LS and FN at 24 months.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Hiramatsu R, Ubara Y, Sawa N, et al. Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study. Nephrol Dial Transplant. 2021. PMID: 33544866. doi:10.1093/ndt/gfaa359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。